Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05079113 · ClinicalTrials.gov registry record
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting
A clinical trial of Stage III Melanoma and Stage IV Cutaneous Melanoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 73
- Enrollment target
- 1
- Study location
NCT05079113 is a study of Stage III Melanoma and Stage IV Cutaneous Melanoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 73 participants, above the 44-participant average among 5 other Stage III Melanoma trials with a reported enrollment target (66% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05079113, a study of Stage III Melanoma and Stage IV Cutaneous Melanoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
- 1
- Study location
Study Summary
To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2023-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05079113
The ClinicalTrials.gov registry entry for NCT05079113 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 44-participant average among 5 other Stage III Melanoma trials with a reported enrollment target (66% higher). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage III Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT05079113 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05079113 about?
NCT05079113 is a clinical study titled "Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting". To generate meaningful data regarding ctDNA that would infer risk of recurrence in stage III melanoma patients.
What is the current status of trial NCT05079113?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2019-10-01. Estimated completion is 2023-04-04.
What conditions does trial NCT05079113 study?
This clinical trial studies the following conditions: Stage III Melanoma, Stage IV Cutaneous Melanoma.
Who is sponsoring clinical trial NCT05079113?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05079113 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Decitabine in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
COMPLETED · Phase 1
-
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.